A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: Protocol for the ASPREE-Fracture substudy
Barker, Anna L., McNeil, John J., Seeman, Ego, Ward, Stephanie A., Sanders, Kerrie M., Khosla, Sundeep, Cumming, Robert G., Pasco, Julie A., Bohensky, Megan A., Ebeling, Peter E., Woods, Robyn L., Lockery, Jessica E., Wolfe, Rory, Talevski, Jason and ASPREE Investigator Group. (2016). A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: Protocol for the ASPREE-Fracture substudy. Injury Prevention. 22(4), pp. 297-301. https://doi.org/10.1136/injuryprev-2015-041655
|Authors||Barker, Anna L., McNeil, John J., Seeman, Ego, Ward, Stephanie A., Sanders, Kerrie M., Khosla, Sundeep, Cumming, Robert G., Pasco, Julie A., Bohensky, Megan A., Ebeling, Peter E., Woods, Robyn L., Lockery, Jessica E., Wolfe, Rory, Talevski, Jason and ASPREE Investigator Group|
Background: Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. Observational studies suggest that aspirin may reduce fracture risk. While these studies provide room for optimism, randomised controlled trials are needed. This paper describes the rationale and design of the ASPirin in Reducing Events in the Elderly ( ASPREE )-Fracture substudy, which aims to determine whether daily low-dose aspirin decreases fracture risk in healthy older people.
Methods: ASPREE is a double-blind, randomised, placebo-controlled primary prevention trial designed to assess whether daily active treatment using low-dose aspirin extends the duration of disability-free and dementia-free life in 19 000 healthy older people recruited from Australian and US community settings. This substudy extends the ASPREE trial data collection to determine the effect of daily low-dose aspirin on fracture and fall-related hospital presentation risk in the 16 500 ASPREE participants aged ≥70 years recruited in Australia. The intervention is a once daily dose of enteric-coated aspirin ( 100 mg ) versus a matching placebo, randomised on a 1:1 basis. The primary outcome for this substudy is the occurrence of any fracture—vertebral, hip and non-vert-non-hip—occurring post randomisation. Fall-related hospital presentations are a secondary outcome.
Discussion: This substudy will determine whether a widely available, simple and inexpensive health intervention—aspirin—reduces the risk of fractures in older Australians. If it is demonstrated to safely reduce the risk of fractures and serious falls, it is possible that aspirin might provide a means of fracture prevention.
Trial registration number: The protocol for this substudy is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000347561).
|Journal citation||22 (4), pp. 297-301|
|Publisher||BMJ Publishing Group|
|Digital Object Identifier (DOI)||https://doi.org/10.1136/injuryprev-2015-041655|
|PubMed Central ID||PMC4879092|
|Open access||Published as green open access|
|Funder||National Health and Medical Research Council (NHMRC)|
|Research Group||Institute for Health and Ageing|
|Author's accepted manuscript|
File Access Level
File Access Level
|Online||21 May 2015|
|Publication process dates|
|Accepted||21 Apr 2015|
Author's accepted manuscript
|License: CC BY-NC 4.0|
|File access level: Open|
7views this month
1downloads this month